Levipil XR 750 Tablet contains Levetiracetam 750 mg, an antiepileptic medication indicated for the treatment of partial-onset seizures, myoclonic seizures, and primary generalized tonic-clonic seizures in patients with epilepsy. Levetiracetam acts by modulating synaptic neurotransmitter release through binding to the synaptic vesicle protein SV2A, thereby reducing neuronal excitability and seizure propagation. Levipil XR is an extended-release formulation designed to maintain stable plasma concentrations over a 24-hour period, allowing once-daily dosing and improving patient compliance. It is generally well-tolerated, with common adverse effects including somnolence, dizziness, headache, and fatigue. Dose adjustments may be necessary in patients with renal impairment. Levipil XR should be used under medical supervision, with gradual dose titration to minimize adverse effects. It is important to adhere to prescribed dosing schedules and not discontinue therapy abruptly to avoid seizure exacerbation. Levipil XR may be used as monotherapy or adjunctive therapy in epilepsy management. Caution is advised when used concomitantly with other central nervous system depressants. Regular monitoring and follow-up are recommended to assess therapeutic response and tolerability. This medication is contraindicated in patients with known hypersensitivity to Levetiracetam or any of its excipients.